Barinthus Biotherapeutics plc Sponsored ADR BRNS 深 滬
等待開盤 04-17 09:30:00 美东时间
0.591
-0.002
-0.34%
華盛通- 最 高0.61
- 今 開0.609
- 成交量 1.62万股
- 最 低 0.59
- 昨 收 0.593
- 總市值 2414.17万
- 52周最高 2.92
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 0.512
- 委 比 26.08%
- 總股本 4084.89万
- 歷史最高 17.99
- 量 比 0.78
- 振 幅 3.37%
- 歷史最低 0.512
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Barinthus Biotherapeutics Q4 EPS $(0.27) Beats $(0.40) Estimate
Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.40) by 32.5 percent. This is a 47.06 percent increase over losses of $(0.51) per
03-13 20:07
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 23.3% to $0.16 during Tues...
03-11 05:06
Barinthus Bio Issues Update On First-In-Human Phase 1 Trial Of VTP-1000 In Adults With Celiac Disease
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000 was well-tolerated with no treatment-related SAEsThe MAD portion
2025-12-10 21:01
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
2025-11-18 15:28
HC Wainwright & Co. Maintains Buy on Barinthus Biotherapeutics, Raises Price Target to $4
HC Wainwright & Co. analyst Yi Chen maintains Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and raises the price target from $3 to $4.
2025-11-17 20:29
ChemDiv To Continue R&D Support As Clywedog Merges With Barinthus Therapeutics; Combined Entity To Trade Under Ticker CLYD On Nasdaq
ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics as the company
2025-10-24 23:05
ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics
SAN DIEGO, Oct. 24, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clin...
2025-10-24 23:00
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders
NEW YORK, Oct. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
2025-10-17 11:58
Barinthus Biotherapeutics And Clywedog Therapeutics Enters Into A Definitive All-Stock Merger Agreement To Form Combined Company; Before Transaction Closes The Combined Company May Initiate Partial Tender Offer To Purchase Up To $27M Worth Of Its Outstanding Shares Held By Barinthus Bio Shareholders
Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio"), an immunology and inflammation company focused on developing therapies that promote immune tolerance, and Clywedog Therapeutics, Inc. ("Clywedog"), a private
2025-09-30 20:18
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Equillium (NASDAQ:EQ) shares moved upwards by 98.9% to $0.98 during Mo...
2025-08-12 01:06
